ERS140940 SAMEA1691818 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691818 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD86.post broker name ArrayExpress clinical information FirstPostiveViralLoad 5weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD86 sample name E-MTAB-1130:SIV.BD86.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140939 SAMEA1691834 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691834 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.4340.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 12weeks common name Rhesus monkey disease state simian immunodeficiency virus individual 4340 sample name E-MTAB-1130:SIV.4340.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140938 SAMEA1691831 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691831 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.4340.post broker name ArrayExpress clinical information FirstPostiveViralLoad 12weeks common name Rhesus monkey disease state simian immunodeficiency virus individual 4340 sample name E-MTAB-1130:SIV.4340.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140941 SAMEA1691823 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691823 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:AD.BD12.post broker name ArrayExpress clinical information FirstPostiveViralLoad 1weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD12 sample name E-MTAB-1130:AD.BD12.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140942 SAMEA1691827 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691827 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.4356.post broker name ArrayExpress clinical information FirstPostiveViralLoad 2weeks common name Rhesus monkey disease state simian immunodeficiency virus individual 4356 sample name E-MTAB-1130:SIV.4356.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140943 SAMEA1691829 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691829 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD17.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 9weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD17 sample name E-MTAB-1130:SIV.BD17.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140944 SAMEA1691832 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691832 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:AD.BD56.post broker name ArrayExpress clinical information FirstPostiveViralLoad 1weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD56 sample name E-MTAB-1130:AD.BD56.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140945 SAMEA1691835 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691835 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD20.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 12weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD20 sample name E-MTAB-1130:SIV.BD20.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140946 SAMEA1691833 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:40Z ENA-LAST-UPDATE 2018-03-08T15:46:19Z External Id SAMEA1691833 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:40Z INSDC last update 2018-03-08T15:46:19Z INSDC status public Submitter Id E-MTAB-1130:SIV.4356.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 2weeks common name Rhesus monkey disease state simian immunodeficiency virus individual 4356 sample name E-MTAB-1130:SIV.4356.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140947 SAMEA1691828 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691828 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD20.post broker name ArrayExpress clinical information FirstPostiveViralLoad 12weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD20 sample name E-MTAB-1130:SIV.BD20.post sampling time point post-vaccination 1weeks scientific_name Macaca mulatta ERS140948 SAMEA1691826 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691826 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:AD.BD76.post broker name ArrayExpress clinical information FirstPostiveViralLoad 4weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD76 sample name E-MTAB-1130:AD.BD76.post sampling time point post-vaccination 26weeks scientific_name Macaca mulatta ERS140949 SAMEA1691821 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691821 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD86.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 5weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD86 sample name E-MTAB-1130:SIV.BD86.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140950 SAMEA1691822 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691822 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:AD.BD74.post broker name ArrayExpress clinical information FirstPostiveViralLoad 2weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD74 sample name E-MTAB-1130:AD.BD74.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140951 SAMEA1691820 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691820 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD91.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 2weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD91 sample name E-MTAB-1130:SIV.BD91.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140952 SAMEA1691837 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691837 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:AD.BD34.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 1weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD34 sample name E-MTAB-1130:AD.BD34.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140953 SAMEA1691836 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691836 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:AD.BD34.post broker name ArrayExpress clinical information FirstPostiveViralLoad 1weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD34 sample name E-MTAB-1130:AD.BD34.post sampling time point post-vaccination 26weeks scientific_name Macaca mulatta ERS140954 SAMEA1691838 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691838 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD91.post broker name ArrayExpress clinical information FirstPostiveViralLoad 2weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD91 sample name E-MTAB-1130:SIV.BD91.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140955 SAMEA1691817 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691817 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:AD.BD74.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 2weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD74 sample name E-MTAB-1130:AD.BD74.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140956 SAMEA1691819 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:21Z External Id SAMEA1691819 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:21Z INSDC status public Submitter Id E-MTAB-1130:AD.BD56.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 1weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD56 sample name E-MTAB-1130:AD.BD56.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140957 SAMEA1691825 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:23Z External Id SAMEA1691825 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:23Z INSDC status public Submitter Id E-MTAB-1130:AD.BD76.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 4weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD76 sample name E-MTAB-1130:AD.BD76.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta ERS140958 SAMEA1691830 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:41Z ENA-LAST-UPDATE 2018-03-08T15:46:23Z External Id SAMEA1691830 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:41Z INSDC last update 2018-03-08T15:46:23Z INSDC status public Submitter Id E-MTAB-1130:SIV.BD17.post broker name ArrayExpress clinical information FirstPostiveViralLoad 9weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD17 sample name E-MTAB-1130:SIV.BD17.post sampling time point post-vaccination 30weeks scientific_name Macaca mulatta ERS140959 SAMEA1691824 9544 Macaca mulatta Protocols: Two groups of six RMs were immunized with either the attenuated SIVDnef virus (group 1, SIV), which establishes a persistent low-level infection and induces protective immunity against high dose challenges with SIVmac, or with two doses of an AdHu5 vector expressing Gag of SIVmac239 (AdHu5gag) (group 2, AD), that was given at a two-month interval with the first dose given at the time of the SIVDnef inoculation to group 1. All RMs were challenged with ten weekly intra-rectal low-doses of SIVmac251 at a week interval starting nine months after the initial vaccination. During this period and for an additional eight weeks afterwards viral loads were measured by RT-PCR. Number of weeks after the first challenge when positive viral load was detected was used as FirstPostiveViralLoad factor. PBMC from whole blood were isolated using Ficoll gradient. ENA-FIRST-PUBLIC 2012-12-31T17:01:45Z ENA-LAST-UPDATE 2018-03-08T16:01:18Z External Id SAMEA1691824 INSDC center name Wistar Genomics Facility INSDC first public 2012-12-31T17:01:45Z INSDC last update 2018-03-08T16:01:18Z INSDC status public Submitter Id E-MTAB-1130:AD.BD12.pre broker name ArrayExpress clinical information FirstPostiveViralLoad 1weeks common name Rhesus monkey disease state simian immunodeficiency virus individual BD12 sample name E-MTAB-1130:AD.BD12.pre sampling time point pre-vaccination 0weeks scientific_name Macaca mulatta